CLINICAL TRIALS PROFILE FOR ESTRADIOL ACETATE

All Clinical Trials for estradiol acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000897 ↗	A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.
NCT00001259 ↗	A Treatment Study for Premenstrual Syndrome (PMS)	Completed	National Institute of Mental Health (NIMH)	Phase 1	1992-08-11	This study examines the effects of estrogen and progesterone on mood, the stress response, and brain function and behavior in women with premenstrual syndrome. Previously this study has demonstrated leuprolide acetate (Lupron (Registered Trademark)) to be an effective treatment for PMS. The current purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in women with PMS. PMS is a condition characterized by changes in mood and behavior that occur during the second phase of the normal menstrual cycle (luteal phase). This study will investigate possible hormonal causes of PMS by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. The results of these hormonal studies will be compared between women with PMS and healthy volunteers without PMS (see also protocol 92-M-0174). At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
NCT00044837 ↗	Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to find out if the anti-HIV drugs nelfinavir (NFV), lopinavir/ritonavir (LPV/r), and efavirenz (EFV) change the amount of estrogen in the blood when taken along with hormone replacement therapy (HRT) for menopause. HRT can be helpful for treating bothersome symptoms of menopause. However, it is not routinely used in HIV-infected postmenopausal women because it is not known how HRT interacts with anti-HIV drugs. The information obtained from this study will help doctors make recommendations for HRT in postmenopausal HIV-infected women.
NCT00089414 ↗	Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives	Terminated	National Institute of Mental Health (NIMH)	Phase 2	2004-07-01	This study will determine whether uninterrupted treatment with birth control pills over several menstrual cycles prevents severe premenstrual syndrome (PMDD). Previous studies have shown that the hormones estrogen and progesterone regulate mood in women with MRMD. This study will use various treatment regimens with birth control pills and placebo (sugar pill) to clarify the relationships among estrogen and progesterone, the menstrual cycle, and mood. Healthy women between 18 and 45 years of age who menstruate may be eligible for this 15-week study. Candidates are screened with a physical examination, blood and urine tests, an electrocardiogram, and 3 months of symptoms ratings to confirm MRMD. Participants are randomly assigned to one of three treatment groups. Group 1 takes a birth control pill every day and on three occasions takes a placebo capsule. Group 2 takes a birth control pill most but not all days and on three occasions takes a placebo capsule. Group 3 takes a birth control pill every day and on three occasions takes another medication called CDB-2914 that causes menstrual bleeding to occur. Participants come to the NIH clinic every other week for blood tests and measurement of vital signs (blood pressure, pulse, and temperature) and to complete symptoms ratings scales. Subjects who develop breakthrough bleeding (menstruation earlier than expected) will have a transvaginal ultrasound. For this procedure, a probe is inserted into the vagina for about 10 minutes. The probe gives off and receives sound waves that can be used to form a picture of the endometrium (lining of the uterus). ...
NCT00127075 ↗	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	Unknown status	Hospices Civils de Lyon	Phase 3	2005-06-01	Multiple sclerosis (MS) affects 1 in 1000 people in western countries, mainly women in their childbearing years. It is an autoimmune disease of the central nervous system (CNS), which results in a chronic focal inflammatory response with subsequent demyelination and axonal loss. Recent prospective studies reported a significant decline by two-thirds in the rate of relapses during the third trimester of pregnancy and a significant increase by two-thirds during the first three months post-partum by comparison to the relapse rate observed during the year prior to the pregnancy (Confavreux et al., 1998). These dramatic changes in the relapse rate occur at a time when the impregnation of many substances (among which, sexual steroids) is at its highest, before a dramatic decline to the pre-pregnancy levels, immediately following delivery. It may be hypothesized that sexual steroids could exert beneficial effects through a modulation of the immune state with a lowering of the pro-inflammatory lymphocyte responses of the Th1 type and an enhancement of the anti-inflammatory responses of the Th2 type. They may also play a direct role in the remyelination of central nervous system lesions, as they do in the peripheral nervous system. The POPART'MUS study is a European, multicentre, randomized, placebo-controlled and double-blind clinical trial, which aims to prevent MS relapses related to the post-partum condition, by administering high doses of progestin (nomegestrol acetate), in combination with endometrial protective doses of estradiol. Treatment will be given immediately after delivery and continuously during the first three months post-partum. Assuming the results of the trial to be positive, this new treatment could be considered in the relapsing-remitting phase of the disease in women afar from pregnancy and post-partum.
NCT00163072 ↗	Pharmacokinetics and Safety of Transdermal Megestrol Acetate	Withdrawn	Milton S. Hershey Medical Center	Phase 4	2005-10-01	Rationale: Megestrol acetate (Megace®) is a progestin analog that is FDA approved for the palliative treatment of breast and endometrial carcinoma. It is also commonly used as an appetite stimulant, particularly in HIV and cancer patients with poor appetite from their primary disease and/or their therapy. Megace is well absorbed orally, however, many patients, particularly younger ones have difficulty taking oral medications. Transdermal progestins are available and are FDA approved. For example, Ortho EvraTM is a transdermal contraceptive patch containing an estrogen (ethinyl estradiol) and a progestin (norelgestromin). Key Objectives: Compare the pharmacokinetics of orally administered vs. transdermal Megace and determine if there are any local side effects of the transdermal route.
NCT00184795 ↗	Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations	Completed	Novo Nordisk A/S	Phase 3	2004-05-28	This trial is conducted in Europe. Postmenopausal women with moderate to severe hot flashes have been recruited into the trial. The earliest effect of ultra low dose HRT (hormone replacement therapy) on frequency and severity of menopausal symptoms, bleeding patterns and safety of different hormonal combinations will be evaluated and compared to placebo over the six month treatment period.

Clinical Trial Conditions for estradiol acetate

Condition Name

Condition Name for estradiol acetate
Intervention	Trials
Contraception	19
Endometriosis	12
Healthy	8
Menopause	8

Condition MeSH

Condition MeSH for estradiol acetate
Intervention	Trials
Endometriosis	15
Leiomyoma	14
Hemorrhage	13
Myofibroma	13

Clinical Trial Locations for estradiol acetate

Trials by Country

Trials by Country for estradiol acetate
Location	Trials
United States	547
Poland	40
Hungary	25
Canada	21
South Africa	19

Trials by US State

Trials by US State for estradiol acetate
Location	Trials
Florida	28
California	25
Virginia	23
Illinois	23
Washington	22

Clinical Trial Progress for estradiol acetate

Clinical Trial Phase

Clinical Trial Phase for estradiol acetate
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for estradiol acetate
Clinical Trial Phase	Trials
Completed	71
Recruiting	14
Unknown status	13

Clinical Trial Sponsors for estradiol acetate

Sponsor Name

Sponsor Name for estradiol acetate
Sponsor	Trials
Merck Sharp & Dohme Corp.	13
Myovant Sciences GmbH	12
AbbVie	6

Sponsor Type

Sponsor Type for estradiol acetate
Sponsor	Trials
Other	85
Industry	80
NIH	14

Estradiol acetate Market Analysis and Financial Projection

Last updated: April 28, 2026

Estradiol Acetate: Clinical Trial Update, Market Analysis, and Projections

What is the current clinical-trials and regulatory footprint for estradiol acetate?

Estradiol acetate is an estrogen prodrug in which esterification (acetate) alters pharmacokinetics relative to estradiol itself. It is clinically developed and marketed in multiple geographies primarily for hormone therapy indications (notably menopausal symptoms and related estrogen-deficiency states).

Clinical development status (high-level):

• Dosing strategy: Estradiol acetate is typically positioned as an estrogen replacement option where oral or depot formulations can be used to modulate exposure.
• Trial focus: Clinical programs for estradiol acetate concentrate on symptom control, endometrial safety (where relevant), and pharmacokinetic (PK) performance versus estradiol comparators.
• Endpoints used across estrogen therapies: vasomotor symptom scores, bleeding patterns, estradiol exposure (Cmax, Tmax, AUC), and biomarkers of estrogenic activity.

Regulatory pattern (high-level):

• Global authorization appears product- and route-specific. Where approved, approvals are tied to formulation and dosing regimen rather than the molecule alone.
• Safety monitoring emphasis: estrogen class risks include endometrial hyperplasia, thromboembolic risk, and breast cancer risk depending on patient population and regimen.

What does the market for estradiol acetate look like by demand driver and competitive set?

Estradiol acetate participates in the broader estrogen hormone therapy market. In most mature markets, competitive dynamics depend more on formulation, payer coverage, and dosing convenience than on molecule differentiation alone.

Demand drivers

• Menopause prevalence and persistence: Women living longer drives sustained use of estrogen therapy.
• Symptom management adherence: Efficacy in vasomotor symptoms and tolerability drive continuity.
• Shift toward convenient regimens: Patients and prescribers prefer dosing schedules aligned with adherence goals.

Competitive set

Estradiol acetate competes within the estrogen therapy landscape, principally against:

• Other estradiol ester prodrugs and estradiol itself (route- and PK-dependent)
• SERM and combination strategies where class switching is common in practice
• Route-differentiated products (oral, transdermal, intramuscular/depot, vaginal where indicated)

What differentiates outcomes in this segment

• PK and bleeding profile (especially where unopposed estrogen is relevant)
• Endometrial protection strategy (paired progestogens when required)
• Dosing frequency and device usability (adherence economics)

How large is the addressable market and where does growth come from?

A precise, molecule-specific revenue figure for estradiol acetate is typically not disclosed in public datasets the way it is for leading single-branded products, because accounting is often tied to formulation and market reporting codes. Practically, market sizing is done by mapping estradiol acetate to the estrogen therapy category and then assessing share capture based on approved products by geography.

Market sizing approach used by analysts

1. Start with the estrogen hormone therapy category size (by geography).
2. Split by:
   • menopause symptom therapies
   • route category (oral vs depot vs transdermal vs vaginal)
   • patient segments (surgical menopause, perimenopause, postmenopause)
3. Apply a route and formulation share proxy for estradiol acetate where it is authorized.

Growth vectors

• Aging population supports baseline growth.
• Therapy substitution cycles (switching between routes) can create demand for specific formulations.
• Local payer formulary access often determines which estrogen products gain sustained share.

What is the commercial outlook and projection path for estradiol acetate?

The projection for estradiol acetate should be modeled as a share-of-category outcome under constraints:

• Formulation approvals determine where revenue can exist.
• Safety and labeling determine switching behavior and persistence.
• Competitor pricing and coverage shape uptake.

Projection framework (what to model)

• Units: number of treated patients or prescriptions by geography and route.
• ASP and mix: average selling price by formulation strength and regimen.
• Persistence: continuation rates for menopausal symptom control.
• Channel: retail vs institutional influence by country.

Base-case logic

• If estradiol acetate maintains or expands formulary access in core markets, share can stabilize and grow with the category.
• If coverage shifts toward other estrogen routes (often transdermal for tolerability profiles), estradiol acetate growth can lag category growth.

Upside and downside drivers

• Upside: new approvals for additional routes/strengths, improved PK/bleeding outcomes in new clinical packages, and stronger payer positioning.
• Downside: unfavorable comparative outcomes, tighter safety restrictions, and competitive displacement by more established products.

What are the key clinical evidence themes that affect market access?

Clinical evidence for estrogen therapies tends to concentrate on three decision points that drive prescribing and reimbursement:

1) Efficacy in symptom control

• Reduction in vasomotor symptoms is central.
• Consistency of response affects guideline adoption and persistence.

2) Endometrial safety (where relevant)

• Bleeding pattern outcomes influence patient continuation.
• Combined regimens (estrogen plus progestogen) shape label positioning in many jurisdictions.

3) PK and tolerability

• Cmax, Tmax, AUC alignment with estradiol pharmacodynamics affects both onset and tolerability.
• Route and depot behavior influence steady-state exposure and side effect profiles.

What should investors and R&D planners watch next for estradiol acetate?

For estradiol acetate, the next catalysts are less about exploratory science and more about label expansion, route/formulation optimization, and evidence packages that strengthen comparative positions.

Priority watch items:

• Regulatory updates tied to labeling changes by region and formulation.
• Comparative clinical trials versus estradiol or competing prodrugs in the same route category.
• Real-world persistence indicators (where available) since continuity drives revenue more than initial uptake.

Key Takeaways

• Estradiol acetate functions as an estrogen prodrug and competes within the broader estrogen hormone therapy market where route, formulation, PK, and bleeding profile determine uptake more than molecule novelty.
• Market outcomes are driven by geography-specific approvals, payer formulary placement, and persistence for menopausal symptom control.
• Projections should be modeled as share-of-category constrained by authorization by route and regimen, then adjusted for formulary access and competitive displacement.

FAQs

1) Is estradiol acetate marketed as a standalone product everywhere?

No. Commercial availability is typically tied to specific formulations and approvals by region, so product-level authorization governs revenue potential.

2) What endpoints matter most for estradiol acetate’s market access?

Clinical packages usually emphasize vasomotor symptom efficacy, bleeding patterns, endometrial safety where relevant, and PK exposure metrics.

3) How does estradiol acetate compete against estradiol itself?

Competition is typically route and PK dependent. Products that deliver steadier exposure and better tolerability often gain switching advantage.

4) What is the biggest lever in projections for estradiol acetate?

Formulary access and persistence, which determine whether the product can convert category growth into sustained share.

5) Are comparative trials required to expand use?

In practice, comparative evidence versus relevant standards and within the same route category often influences guideline adoption and payer preferences.

---

References

[1] U.S. FDA. Drug Approval Reports and Product Labeling database (accessed via public FDA resources).
[2] European Medicines Agency (EMA). EPARs and assessment reports for estradiol-containing products and estrogen hormone therapy labeling frameworks.
[3] World Health Organization (WHO). ATC classification framework and menopause hormone therapy categorization background.
[4] ClinicalTrials.gov. Estradiol acetate-related clinical trial records (search results for molecule name and synonyms).
[5] Published review literature on estrogen therapy clinical endpoints for menopause (vasomotor symptoms, bleeding pattern, and endometrial safety).